{"id":47308,"date":"2022-08-15T23:01:52","date_gmt":"2022-08-15T21:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lucid-diagnostics-provides-business-update-and-preliminary-second-quarter-2022-financial-results\/"},"modified":"2022-08-15T23:01:52","modified_gmt":"2022-08-15T21:01:52","slug":"lucid-diagnostics-provides-business-update-and-preliminary-second-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lucid-diagnostics-provides-business-update-and-preliminary-second-quarter-2022-financial-results\/","title":{"rendered":"Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results"},"content":{"rendered":"
\n

\nEsoGuard test volume increased 60% for quarter and over 300% annually<\/i>\n<\/p>\n

\nCLIA-Certified LucidDx Labs fully operational and billing as an independent entity<\/i>\n<\/p>\n

\nConference call to be held today at 4:30 PM EDT<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–$LUCD<\/a> #investing<\/a>—Lucid Diagnostics Inc.<\/b><\/a> (Nasdaq: LUCD) (\u201cLucid\u201d, the \u201cCompany\u201d), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc.<\/b><\/a> (Nasdaq: PAVM, PAVMZ) (\u201cPAVmed\u201d), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.\n<\/p>\n

<\/a><\/p>\n

\nConference Call and Webcast<\/b>\n<\/p>\n

\nA conference call and webcast for today\u2019s business update and second quarter 2022 financial results will take place at 4:30 PM EDT. To access the conference call, listeners should dial 877-407-0789 toll-free in the U.S., and international listeners should dial 201-689-8562 and ask to join the \u201cLucid Diagnostics Business Update Conference Call\u201d. The conference call will be available live via a webcast and for replay at the investor relations section of the Company\u2019s website at https:\/\/ir.luciddx.com<\/a>. Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 toll-free in the U.S. or 412-317-6671, followed by the PIN number: 13730496.\n<\/p>\n

\nBusiness Update Highlights<\/b>\n<\/p>\n

\n\u201cThe past quarter and recent weeks have been a transformational period for Lucid, during which we have achieved key milestones which represent the final bricks in the foundation upon which we are building this company and driving its long-term growth strategy,\u201d said Lishan Aklog, M.D.<\/a>, Lucid\u2019s Chairman and Chief Executive Officer. \u201cWe now have a consensus among the major specialty societies which explicitly support the use of our products to prevent esophageal cancer deaths through early detection of esophageal precancer, and further expand our addressable market. And, for the first time, we are truly, from an operational perspective, an independent full-service medical diagnostic company capable of fulfilling the clinical and economic potential of these products.\u201d\n<\/p>\n

\nHighlights from the second quarter and recent weeks include:\n<\/p>\n